检索结果-南通市图书馆

Novel approaches to therapeutics in pancreatic adenocarcinoma: vitamin C and tumor treatment fields

Journal of Cancer Metastasis and Treatment 2021年第1期7卷 284-299页

作者： Laith Abushahin Travis Jones Jonathan Song Terence M.Williams Haseebah Shahzad anne noonan Arthur G.James Comprehensive Cancer Center and Richard J.Solove Research Institute The Ohio State University Medical CenterColumbusOH 43210USA Department of Internal Medicine Division of Medical OncologyThe Ohio State UniversityColumbusOH 43210USA Department of Mechanical&Aerospace Engineering The Ohio State UniversityColumbusOH 43210USA Department of Radiation Oncology The Ohio State University Medical CenterColumbusOH 43210USA

Pancreatic ductal adenocarcinoma(PDAC)is a lethal disease with limited therapeutic *** extensive clinical research over the past several decades,meaningful improvements in care standards have been challenging to *** efforts are underway on several fronts,including cytotoxic chemotherapy combinations,immunotherapy,and targeted *** this review,we chose to focus less on mainstream avenues of clinical research in PDAC and highlight some novel and innovative research efforts that are typically outside the spotlight of *** of these novel approaches include pharmacologic vitamin C and electromagnetic *** review’s scope is to present the biological basis of the anti-cancer potential and the early clinical data,as well as the future landscape of these agents,including ongoing clinical trials in these therapeutic avenues.

关键词： Pancreas cancer vitamin C ascorbate tumor treatment fields induced electromagnetic field electromagnetic field therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma

引用

World Journal of Gastroenterology 2019年第28期25卷 3704-3721页

作者： Clifford Akateh Sylvester M Black Lanla Conteh Eric D Miller anne noonan Eric Elliott Timothy M Pawlik Allan Tsung Jordan M Cloyd Department of Surgery The Ohio State University Wexner Medical Center Columbus OH 43210 United States Division of Transplant Surgery Department of Surgery The Ohio State University Wexner Medical Center Columbus OH 43210 United States Division of Gastroenterology Hepatology and Nutrition Department of Internal Medicine The Ohio State University Wexner Medical Center Columbus OH 43210 United States Department of Radiation Oncology The Ohio State University Wexner Medical Center Columbus OH 43210 United States Division of Medical Oncology Department of Internal Medicine The Ohio State University Wexner Medical Center Columbus OH 43210 United States Division of Diagnostic Radiology Department of Radiology The Ohio State University Wexner Medical Center Columbus OH 43210 United States Division of Surgical Oncology Department of Surgery The Ohio State University Wexner Medical Center Columbus OH 43210 United States

Hepatocellular carcinoma (HCC) is the most common liver malignancy worldwide and a major cause of cancer-related mortality for which liver resection is an important curative-intent treatment option. However, many patients present with advanced disease and with underlying chronic liver disease and/or cirrhosis, limiting the proportion of patients who are surgical candidates. In addition, the development of recurrent or de novo cancers following surgical resection is common. These issues have led investigators to evaluate the benefit of neoadjuvant and adjuvant treatment strategies aimed at improving resectability rates and decreasing recurrence rates. While high-level evidence to guide treatment decision making is lacking, recent advances in locoregional and systemic therapies, including antiviral treatment and immunotherapy, raise the prospect of novel approaches that may improve the outcomes of patients with HCC. In this review, we evaluate the evidence for various neoadjuvant and adjuvant therapies and discuss opportunities for future clinical and translational research.

关键词： Hepatocellular carcinoma Neoadjuvant therapy Adjuvant therapy Neoplasm recurrence Hepatectomy Liver cirrhosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma

引用

World Journal of Clinical Oncology 2019年第3期10卷 149-160页

作者： Jennifer Wu Merly Contratto Krishna P Shanbhogue Gulam A Manji Bert H O'Neil anne noonan Robert Tudor Ray Lee Division of Hematology and Oncology Perlmutter Cancer CenterNew York University School of Medicine Department of Radiology at New York University School of Medicine Division of Hematology and Oncology Columbia University Medical Center Division of Hematology and Oncology Indiana University Division of Hematology and Oncology Ohio State University Medical Center Roche Pharmaceutical Company Roche and Teclison Pharmaceutical Company

BACKGROUND Hypoxia-inducible factor 1α(HIF-1α) is a gene that regulates tumor survival,neovascularization and invasion. Overexpression of HIF-1α correlates with poor prognosis in hepatocellular carcinoma(HCC). RO7070179 is a HIF-1α inhibitor that decreases HIF-1α mRNA and its downstream targets, it could be a potential treatment in *** To evaluate safety and preliminary activity of RO7070179 in patients with previously treated HCC, with focus on a patient with prolonged response to *** In the preclinical study of RO7070179 in a HCC xenograft model, the mice wereseparated into 4 groups with each group received doses of 0, 3, 10 and 30 mg/kg for total 10 doses. HCC patients who failed at least one line of systemic treatment,received RO7070179 as a weekly infusion, each cycle is 6 wk. We evaluated the safety and HIF-1α mRNA levels of *** Preclinical evaluation of RO7070179 in orthotopic HCC xenograft model showed no significant differences in HCC tumor weight between the 3 and 10 mg/kg groups. However, dose of 10 mg/kg of RO7070179, has shown 76% reduction of the amount of HIF-1α mRNA in HCC tissue. In the phase 1 b study of RO7070179 in previously treated HCC patients, 8 out of 9 were evaluable: 1 achieved PR and1 SD. The patient with PR responded after 2 cycles treatments, which has been maintained for 12 cycles. This patient also showed reduction in perfusion of dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI) after 1 cycle of treatment. After 1 cycle of treatment, both patients with PR and SD showed decrease in HIF-1α mRNA at the root of biopsies(each biopsy was divided into 2 specimens, the tip and the root).CONCLUSION RO7070179 can reduce HIF-1α mRNA level in HCC patients with SD or PR. It is well tolerated at 10 mg/kg, with transaminitis as the dose of increased *** study indicates that RO7070179 might benefit HCC patients, and an early signal for clinical benefit can potentially be predicted through changes

关键词： Hepatocellular carcinoma Hypoxia-inducible factor 1α RO7070179,Superresponder Dynamic contrast-enhanced-magnetic resonance imaging

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

科聚亚推出更高效阻燃剂产品Firemaster~

引用

塑料制造 2006年第8期 31-31页

作者： anne noonan 科聚亚

科聚亚公司(康普顿/大湖化学)(Chemtura Corporation:Crompton/Great Lakes)推出了Firemaster(R)600和Firemaster(R)602这两个牌号的用于聚氨酯软泡沫的新型阻燃剂,阻燃效果比之前推出的Firemaster(R)550和Firemaster(R)552高出约10%.

关键词：高效阻燃剂最终产品 Crompton 阻燃效果物理性能加工过程环保特性康普顿泡沫聚氨酯

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：